Sohn: NYSE-listed Estee Lauder’s Northcape Capital pick

Northcape Capital’s Fleur Wright this gives a rare opportunity to buy a high quality company at an attractive price.

David Rogers

Sohn: NYSE-listed Estee Lauder’s Northcape Capital pick

November 15, 2024
Northcape Capital’s Fleur Wright this gives a rare opportunity to buy a high quality company at an attractive price.
Read Transcript

‍It’s one of the best known brands in the world but Estee Lauder has been pummeled.

For Northcape Capital’s Fleur Wright this gives a rare opportunity to buy a high quality company at an attractive price.

In her Sohn Hearts & Minds Conference debut, Ms Wright says Estee Lauder is set to regain its premium share market valuation amid emerging “mega-trends” in the cosmetics industry.

Estee Lauder shares rose five fold in the five-years to the start of 2022. Its skin care and travel retail divisions were driving-double digit organic sales growth and strong margin expansion. The company had an enviable track record and brand and still does.

Despite the initial uncertainty of Covid, e-commerce took off and the removal of travel restrictions in the US and Europe had Estee management primed for China’s reopening.

“But then, just like that, the party stopped,” Wright said.

“China didn’t reopen, Asia slowed, and US and European ‘revenge spend’ abated.

“Estee found itself with too much product in the wrong place at the wrong time.”

At that point the company suffered from an excess of inventory built up to meet demand during the pandemic, losing about 80 percent of its value over the next two years.

At current levels around $US64.83 versus a record high of $US374.20 in early 2022, the share price is well below the levels where Northcape began buying in 2019.

“But I’m here to tell you that the worst is over,” Wright said.

The company now has a restructuring plan to boost its profit by $US1.4bn by 2026.

That’s 80 per cent of the profit that the company delivered last year.

“Now we also have a catalyst after their poor performance in recent years,” Wright said.

“We have a whole new senior management team ready to take estate to the next level.

“Put those earnings on Estee’s historic PE multiple, and you get a share price return that is more than double.

“This is one of those rare times to buy a quality company at an attractive price.”

With a $25bn market capitalisation, the US-listed cosmetics company doesn’t just own the Estee Lauder brand. It has over 20 well known global premium beauty brands.

It’s a big part of why its share price has historically commanded a PE premium of 1.7 times, which is what Northcape paid for the shares when it launched its global equity fund in 2019.

“It’s a great example of the type of high quality business I like to invest in,” Wright said.

“It meets all of North Cape’s quality principles, meaning it can sustainably generate returns well above its cost of capital reinvest and grow and hence to live on long term share price out performance.”

Estee is the third biggest cosmetics maker globally, with huge economies of scale in research and development, manufacturing and marketing. It also dominates in “prestige beauty”, where there’s less competition and brand recognition and luxury reputation are “really hard to replicate”.

It’s also in a growth industry, one where Estee has a long track record of outperforming by over 50 per cent, with mid-single plus organic sales growth for over the past 30 years.

Ongoing China stimulus measures could provide a boost, as while cosmetics are thought to be a discretionary spending item, they have actually historically behaved more Like a staple.

Former CEO Leonard Lauder coined it the “lipstick effect”, after observing the purchases of affordable luxuries like lipstick, actually tended to go up as economic growth rates fell.

“So whilst I might be worried about a recession (in China) in coming years, I’m a whole lot less worried about its impact on Estee,” Wright added.

But she also sees “mega trends” driving long-term growth for Estee Lauder.

Firstly, spending per capita has room to grow because consumers in emerging markets countries are spending only a fraction on beauty products compared to the US, Europe and Japan.

Secondly, consumers tend to spend more on beauty products as they age. For countries like China where population growth has stopped, the average age of people is getting older.

Third, additional growth categories are opening up with the help of innovation into areas like home fragrances. Finally, men are increasingly starting to use cosmetics.

“Together, these factors should help return Estee to its mid- to-high single digit organic growth trajectory, and importantly, I think they can do a whole lot better than this,” Wright said.

“After the recent years of declines, Estee can grow again.”

This article was originally posted by The Australian here.

Licensed by Copyright Agency. You must not copy this work without permission.

‍It’s one of the best known brands in the world but Estee Lauder has been pummeled.

For Northcape Capital’s Fleur Wright this gives a rare opportunity to buy a high quality company at an attractive price.

In her Sohn Hearts & Minds Conference debut, Ms Wright says Estee Lauder is set to regain its premium share market valuation amid emerging “mega-trends” in the cosmetics industry.

Estee Lauder shares rose five fold in the five-years to the start of 2022. Its skin care and travel retail divisions were driving-double digit organic sales growth and strong margin expansion. The company had an enviable track record and brand and still does.

Despite the initial uncertainty of Covid, e-commerce took off and the removal of travel restrictions in the US and Europe had Estee management primed for China’s reopening.

“But then, just like that, the party stopped,” Wright said.

“China didn’t reopen, Asia slowed, and US and European ‘revenge spend’ abated.

“Estee found itself with too much product in the wrong place at the wrong time.”

At that point the company suffered from an excess of inventory built up to meet demand during the pandemic, losing about 80 percent of its value over the next two years.

At current levels around $US64.83 versus a record high of $US374.20 in early 2022, the share price is well below the levels where Northcape began buying in 2019.

“But I’m here to tell you that the worst is over,” Wright said.

The company now has a restructuring plan to boost its profit by $US1.4bn by 2026.

That’s 80 per cent of the profit that the company delivered last year.

“Now we also have a catalyst after their poor performance in recent years,” Wright said.

“We have a whole new senior management team ready to take estate to the next level.

“Put those earnings on Estee’s historic PE multiple, and you get a share price return that is more than double.

“This is one of those rare times to buy a quality company at an attractive price.”

With a $25bn market capitalisation, the US-listed cosmetics company doesn’t just own the Estee Lauder brand. It has over 20 well known global premium beauty brands.

It’s a big part of why its share price has historically commanded a PE premium of 1.7 times, which is what Northcape paid for the shares when it launched its global equity fund in 2019.

“It’s a great example of the type of high quality business I like to invest in,” Wright said.

“It meets all of North Cape’s quality principles, meaning it can sustainably generate returns well above its cost of capital reinvest and grow and hence to live on long term share price out performance.”

Estee is the third biggest cosmetics maker globally, with huge economies of scale in research and development, manufacturing and marketing. It also dominates in “prestige beauty”, where there’s less competition and brand recognition and luxury reputation are “really hard to replicate”.

It’s also in a growth industry, one where Estee has a long track record of outperforming by over 50 per cent, with mid-single plus organic sales growth for over the past 30 years.

Ongoing China stimulus measures could provide a boost, as while cosmetics are thought to be a discretionary spending item, they have actually historically behaved more Like a staple.

Former CEO Leonard Lauder coined it the “lipstick effect”, after observing the purchases of affordable luxuries like lipstick, actually tended to go up as economic growth rates fell.

“So whilst I might be worried about a recession (in China) in coming years, I’m a whole lot less worried about its impact on Estee,” Wright added.

But she also sees “mega trends” driving long-term growth for Estee Lauder.

Firstly, spending per capita has room to grow because consumers in emerging markets countries are spending only a fraction on beauty products compared to the US, Europe and Japan.

Secondly, consumers tend to spend more on beauty products as they age. For countries like China where population growth has stopped, the average age of people is getting older.

Third, additional growth categories are opening up with the help of innovation into areas like home fragrances. Finally, men are increasingly starting to use cosmetics.

“Together, these factors should help return Estee to its mid- to-high single digit organic growth trajectory, and importantly, I think they can do a whole lot better than this,” Wright said.

“After the recent years of declines, Estee can grow again.”

This article was originally posted by The Australian here.

Licensed by Copyright Agency. You must not copy this work without permission.

Disclaimer: This material has been prepared by The Australian, published on Nov 15, 2024. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Vihari Ross of Antipodes. Picture: Louie DouvisVihari Ross of Antipodes. Picture: Louie DouvisVihari Ross of Antipodes. Picture: Louie DouvisVihari Ross of Antipodes. Picture: Louie Douvis
November 5, 2024

Antipodes’ Ross says short-term wealth hinges on US election

The portfolio manager says defensive stocks pose a bigger risk than the magnificent seven for investors that are overexposed to the American sharemarket.

Read More
Antipodes Partners portfolio manager Vihari Ross: ‘We ask where the overvaluation is and where the opportunity is.’ Picture: John FederAntipodes Partners portfolio manager Vihari Ross: ‘We ask where the overvaluation is and where the opportunity is.’ Picture: John FederAntipodes Partners portfolio manager Vihari Ross: ‘We ask where the overvaluation is and where the opportunity is.’ Picture: John FederAntipodes Partners portfolio manager Vihari Ross: ‘We ask where the overvaluation is and where the opportunity is.’ Picture: John Feder
November 5, 2024

Concentration risk key for investors: Antipodes Partners’ Vihari Ross

The concentration risk in global stock indexes that has built up during the strong rise over the past year must now be a key consideration for global investors, according to Vihari Ross.

Read More
JO Hambro Asset Management senior portfolio manager Samir Mehta.JO Hambro Asset Management senior portfolio manager Samir Mehta.JO Hambro Asset Management senior portfolio manager Samir Mehta.JO Hambro Asset Management senior portfolio manager Samir Mehta.
November 5, 2024

The fundie betting big on China – with help from AI

Mr Mehta is sticking to his well-worn strategy: he’s hunting for companies across Asia that aren’t battling intense competition and have management teams focused on costs, cash generation and high payouts to shareholders.

Read More
Beeneet Kothari is ready to shock the Sohn Hearts & Minds event.Beeneet Kothari is ready to shock the Sohn Hearts & Minds event.Beeneet Kothari is ready to shock the Sohn Hearts & Minds event.Beeneet Kothari is ready to shock the Sohn Hearts & Minds event.
October 29, 2024

Why this fundie wants you to ‘wince’ at his stock picks

When fund managers come to pitch their favourite stock at the annual Sohn Hearts & Minds conference, there are two ways they can go: they can play it safe, or they can take a risk and shock the room.

Read More
October 27, 2024

IFM Investors’ Rikki Bannan backs small cap investments to rebound after mixed performance

IFM Investors executive director Rikki Bannan believes this year could be a good one to invest in some select small cap stocks.

Read More
October 22, 2024

Meet the 2024 Conference Managers

Following a global search, the Conference Fund Manager Selection Committee is pleased to share eleven new managers for 2024.

Read More
October 21, 2024

Chris Kourtis is on a winning streak. Here’s his next ASX pick

Chris Kourtis of Ellerston Capital thinks he’s found another winner and thinks it’s the last chance to have a bite at the cherry before the strategy plays out.

Read More
Ellerston Capital portfolio manager Chris Kourtis. Picture: Britta CampionEllerston Capital portfolio manager Chris Kourtis. Picture: Britta CampionEllerston Capital portfolio manager Chris Kourtis. Picture: Britta CampionEllerston Capital portfolio manager Chris Kourtis. Picture: Britta Campion
October 21, 2024

Why Ellerston Capital’s Chris Kourtis plans to back a ‘hated’ stock

Chris Kourtis of Ellerston Capital plans to tip one of the “most hated” stocks in Australia when he presents at the 2024 Sohn Hearts & Minds Conference.

Read More
 ‘We’re riding a wave which started (with) the first silicon chips,’ Alex Pollak says. Picture: Britta Campion ‘We’re riding a wave which started (with) the first silicon chips,’ Alex Pollak says. Picture: Britta Campion ‘We’re riding a wave which started (with) the first silicon chips,’ Alex Pollak says. Picture: Britta Campion ‘We’re riding a wave which started (with) the first silicon chips,’ Alex Pollak says. Picture: Britta Campion
October 14, 2024

Alex Pollak champions rewards of disruptive investment

Alex Pollak’s funds management company Loftus Peak rode the Nvidia wave and he is now looking at more opportunities in disruptive industry stocks.

Read More
October 8, 2024

Sumit Gautam - Why AI won't deliver in 2025 | Scalar Gauge

Sumit Gautam is the Founder of Scalar Gauge and speaks with Equity Mates ahead of his appearance at the Sohn Hearts & Minds conference.

Read More
September 30, 2024

Missed out on Nvidia and Ozempic? This fundie says it’s never too late

Northcape Capital’s Fleur Wright is still kicking herself for not owning market darlings Nvidia and Novo Nordisk, the maker of the weight loss wonder drug Ozempic, before shares of those companies rocketed in 2023.

Read More
September 23, 2024

Scalar Gauge Fund founder Sumit Gautam cautious about over-hyped AI

Tech investor Sumit Gautam carefully avoids the word bubble when describing the investor frenzy surrounding the rise of artificial intelligence, but warns there are dangers of getting caught up in the hype.

Read More
September 9, 2024

The Wellcome Trust’s Nick Moakes made a 100-year bet. It’s paying off

Chief Investment Officer, Nick Moakes raised almost $3 billion at ultra-low rates. Sometimes the long view can be the most profitable.

Read More
Wellcome Trust chief investment officer Nicholas Moakes. Picture: Steven PocockWellcome Trust chief investment officer Nicholas Moakes. Picture: Steven PocockWellcome Trust chief investment officer Nicholas Moakes. Picture: Steven PocockWellcome Trust chief investment officer Nicholas Moakes. Picture: Steven Pocock
September 5, 2024

Honesty the only policy that matters, says Wellcome Trust’s Nicholas Moakes

The chief investment officer of the London-based $71bn Wellcome Trust, Nick Moakes, has a simple rule for the trust’s investment team: “Never invest with anyone who is or has been or should have been in prison.”

Read More
September 5, 2024

Why Howard Marks says you’re making a big mistake

Howard Marks says investors must ignore manic depressive markets and focus on the bigger picture. Rates will be higher for longer and that will bring pain – and opportunity.

Read More
December 10, 2024

Professor Jane Butler: Sparking Hope for Spinal Cord Injuries

In this episode of the Hearts & Minds Podcast, we sit down with Professor Jane Butler to discuss her groundbreaking research into spinal cord injuries.

Read More
impact-podcasts
September 24, 2024

Asian Market Potential with Tom Naughton of Prusik

CIO Charlie Lanchester sits down with Tom Naughton, CIO of Prusik Investment Mgmt. Tom shares his investment philosophy, the opportunities and challenges in Asian markets, and how his 2023 conference stock pick, Swire Pacific (0019.HK), delivered an impressive 30% return.

Read More
investing
September 4, 2024

Building Hearts and Minds with Co-Founders Matthew Grounds and Guy Fowler

In this episode, co-founders Matthew Grounds AM and Guy Fowler OAM discuss their journey in building Hearts & Minds and its philanthropic model that has donated over $70 million to medical research.

Read More
investing
June 25, 2024

Navigating the Resource Sector with Jeremy Bond of Terra Capital

In this episode, we chat with Jeremy Bond, Founder of Terra Capital and HM1 Conference Fund Manager. Tune in for insights into the world of resource investments and the exciting opportunities that lie ahead.

Read More
investing
June 11, 2024

Prof. Nadia Badawi on Cerebral Palsy Breakthroughs and Neonatal Care

Dive deep into the groundbreaking work of Professor Nadia Badawi, an internationally recognised neonatologist and expert in Cerebral Palsy.

Read More
impact-podcasts
May 28, 2024

Investment Insights: Rikki Bannan on Top Picks and Trends

Join us for an engaging episode featuring Rikki Bannan, Portfolio Manager of IFM Investors and HM1 Conference Fund Manager. This episode explores Rikki's career journey, investment strategies, and her 2023 conference stock pick, Telix Pharmaceuticals (ASX.TLX).

Read More
investing
December 6, 2023

Peter Cooper talks building and instilling a culture of humility and excellence

In this episode, our guest is the renowned investor, Peter Cooper, founder and Chief Investment Officer of Cooper Investors (Core Fund Manager). A founding supporter of Hearts and Minds, Peter is a staunch advocate of our model and its philanthropic purpose, actively engaging in every facet of Hearts and Minds.

Read More
investing
November 28, 2023

Jun Bei Liu on her high conviction investment strategy

In this episode, HM1 Chief Investment Officer Charlie Lanchester is joined by Jun Bei Liu. Jun Bei is the Portfolio Manager of Tribeca’s Alpha Plus Fund and since taking over managing the Fund, she has quadrupled AUM.

Read More
investing
November 21, 2023

The world of rare genetic disease research

In this episode, we speak to Associate Professor Gina Ravenscroft. Gina is an Associate Professor in Neurogenetics at the Harry Perkins Institute of Medical Research in Perth. Her research interests are in rare genetic diseases, with a particular focus on neurogenetic diseases in babies and children.

Read More
impact-podcasts
November 14, 2023

Learn what makes a high conviction investment and how to avoid short-term noise

In this episode, our Core Fund Manager Magellan shares how they select top stocks for the HM1 portfolio.

Read More
investing
November 7, 2023

Delve into the world of kids critical care and trauma research

In thie episode, we are joined by Dr. Marino Festa, or Rino for short. He is the Medical Director of NSW Kids ECMO Referral Service and a senior specialist in Paediatric Intensive Care at Children’s Hospital at Westmead.

Read More
impact-podcasts
October 31, 2023

Where Regal's Phil King is searching for opportunities

HM1's CIO, Charlie Lanchester, talks to Phil King of Regal Funds about his passion for stocks, his ongoing search for opportunities, and some of the sectors he’s excited by right now. Phil King of Regal Funds, has been a tremendous supporter of Hearts & Minds since the beginning.

Read More
investing
October 24, 2023

Preventing recurrent miscarriages and birth defects

In this episode, CEO Paul Rayson is joined by renowned biomedical researcher Professor Sally Dunwoodie. Prof. Dunwoodie's groundbreaking work has revolutionised clinical practices and enabled genetic diagnostic tests worldwide. In 2017, her team achieved a double breakthrough with the potential to prevent recurrent miscarriages and various birth defects.

Read More
impact-podcasts
October 17, 2023

Nick Griffin on how he finds global winners

In this episode, CIO Charlie Lanchester chats with Nick Griffin, the founding partner and CIO of Munro Partners, one of HM1's Core Fund Managers. They go over his career to date, reflect on the lessons he’s learned, and trace the decisions that led to him starting Munro.

Read More
investing
October 10, 2023

How A/Prof Matt Call is teaching our body to kill cancer

In this episode, CEO Paul Rayson is joined by WEHI’s Associate Professor Matt Call to talk about his incredible research. Matt’s team teaches and trains the body's own immune cells to target and kill cancer cells.

Read More
impact-podcasts

No results found.

Please try a different search keyword or filter.